This technology involves a series of modified HCT116 colon cancer cell lines in which the BID gene has been completely deleted from both chromosomes using AAV gene targeting. The cells lack all BID expression along with the FADD protein, resulting in robust resistance to apoptosis when exposed to selected anticancer agents. Two extensively characterized clones display these unique features, making them an exceptional model for studying apoptosis pathways and the interplay between intrinsic and extrinsic cell death mechanisms in cancer research.
Description
This approach is differentiated by achieving a full knockout of a critical apoptotic mediator—an outcome that traditional knockdown methods such as RNA interference cannot replicate. Being the first complete BID-null colon cancer cell models available, they provide unprecedented insights into the molecular mechanisms of cancer cell survival and treatment resistance. Their development offers a highly specific and reliable platform for drug efficacy testing and mechanistic studies, thereby opening new avenues for advancing preclinical research and the development of more effective anticancer therapies.
Applications
- Anticancer compound screening platform
- Drug development research tool
- Therapeutic resistance evaluation assay
Advantages
- Offers a reliable model to study apoptosis mechanisms and the interplay between intrinsic and extrinsic pathways.
- Provides a unique tool with complete BID gene knockout, overcoming limitations of partial knockdown methods.
- Enables accurate evaluation of anticancer agent efficacy and resistance mechanisms in cancer research.
- Facilitates in-depth investigations into BID and FADD mediated processes in colon cancer cells.
- Advances cancer biology studies and therapeutic development with a novel, well-characterized cell line model.
IP Status
Research Tool
